Clinical Trial Detail

NCT ID NCT03873818
Title Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

melanoma

Therapies

Ipilimumab + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.